Concepedia

Alexander Niyazov

AN

Statistics

Publications

11

Citations

231

H-Index

10

Active since

2021

Affiliations

Pfizer (United States)(Current)

Institut Gustave Roussy

University of Utah

University Hospitals Seidman Cancer Center

Pfizer (United Kingdom)

Alexander Niyazov is an author at Pfizer (United States) specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2021–2024

11

Publications

11

TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal, Fred Saad, Arun Azad et al. · Future Oncology · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Neoadjuvant Talazoparib in Patients With Germline <i>BRCA1/2</i> Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones et al. · The Oncologist · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study

Pedro C. Barata, Andrea Leith, Amanda Ribbands et al. · The Oncologist · 2023 · 36 citations · Full text

Medicine, Oncology, Urology +16

Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal, Arun Azad, Karim Fizazi et al. · Journal of Clinical Oncology · 2022 · 26 citations

Medicine, Oncology, Pharmacology +16

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study

Pedro C. Barata, Andrea Leith, Amanda Ribbands et al. · The Oncologist · 2023 · 20 citations · Full text

Medicine, Oncology, Urology +17

1–5 of 11